DavidAndrewRisebergMD

Oncology • Lutherville, MD

medical oncologist & hematologist

Join to view full profile

Dr. Riseberg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Riseberg's full profile

Already have an account?

Office
1734 York Rd
Lutherville, MD 21093
Phone+1 410-494-9099

Fax+1 410-825-5307
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
University of MarylandResidency, Internal Medicine, 1989 - 1992
University of Maryland School of MedicineClass of 1989

Certifications & Licensure

MD State Medical License 1990 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013

Clinical Trials

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab Start of enrollment: 2010 Mar 01
Completed
Phase 2
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. Start of enrollment: 2015 Jul 23
Completed
Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

11 citations
Cardiovascular Health among Black and White Breast Cancer Patients Initiating Aromatase Inhibitor Therapy
Lisa Gallicchio, Carla Calhoun, David A. Riseberg, Kathy J. Helzlsouer> ;The Breast Journal. 2017 Mar 1
Response to Dr. Altundag's Letter to the Editor.
Lisa Gallicchio, Carla Calhoun, David A. Riseberg, Kathy J. Helzlsouer> ;The Breast Journal. 2017 Feb 1
9 citations
Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast Cancer.
David A. Riseberg> ;Clinical Medicine Insights. Oncology. 2015 Aug 24
6 citations
A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancer.
Jo Anne Zujewski, Jennifer Eng-Wong, Joyce A. O'Shaughnessy, David Venzon, Catherine Chow, David N. Danforth, David R. Kohler, Georgia Cusack, David Riseberg, Kenneth ...> ;Breast Cancer Research and Treatment. 2003 Sep 1
34 citations
Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer
David N. Danforth, Jo Anne Zujewski, Joyce O'Shaughnessy, David Riseberg, Seth M. Steinberg, Nanette McAtee, Marianne Noone, Catherine Chow, Usha Chaudhry, Marc E. Lip...> ;Annals of Surgical Oncology. 1998 Mar 1
22 citations
Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophag...
Joyce A. O'Shaughnessy, Anthony W. Tolcher, David Riseberg, David Venzon, Jo Anne Zujewski, Marianne Noone, Michelle Gossard, David N. Danforth, Joan Jacobson, Victori...> ;Blood. 1996 Mar 15
9 citations
Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow.
G. N. Schwartz, Frances T. Hakim, JoAnne Zujewski, Janet M. Szabo, R. Cepada, David Riseberg, M. K. Warren, Crystal L. Mackall, A. Setzer, Marianne Noone, Kenneth H. C...> ;British Journal of Haematology. 1996 Feb 1
Late extramedullary relapse following bone marrow transplant for AML presenting as acute renal failure and leukemic ascites.
Riseberg, D. A., Mulvey, K. P., Dahut, W. L., Frame, J. N., Phares, J. C.> ;Bone Marrow Transplant. 1994 Dec
Join now to see all

Press Mentions

The Woman's Doctor: Tips on Breast Cancer FatigueJune 27th, 2022
Mercy Medical Oncologists Drs. David Riseberg and Sandy Kotiah to Appear on Mercy’s Ongoing “MEDOSCOPY” SeriesJune 22nd, 2022
HER2-Positive Breast Cancer Patient Being Treated with Newly Approved DrugsSeptember 30th, 2021
Join now to see all